Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
Your search for apixaban returned 101 results
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.
Apixaban and rivaroxaban are both factor Xa inhibitors.
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients